טימור באזוב

Prof. Baasov was born in 1954 in the Soviet Union and immigrated to Israel in 1974, obtained his BSc and MSc from Tel Aviv University and PhD with Mordechai Sheves at the Weizmann Institute (1981-1986).  Following a postdoctoral research with J. R. Knowles at Harvard University (Chaim Weizmann Postdoctoral Fellow1986-1988) he joined the Schulich Faculty of Chemistry at the Technion and became Full Professor in 2004. His list of prizes and awards includes the Hershel Rich Innovation Award (2005, 2008, 2010), the Technion Excellence in Teaching Award (seven times: 2002, 2006, 2007, 2008, 2010, 2014, 2015), the Jacknow Award for excellence in teaching (2006), the 2016 ICS-ICL Prize for Technological Innovation, and the 2020 NCK Prize for an Outstanding Medicinal Chemist in Israel. He holds the Irving and Jeanette Benveniste Chair in Life Sciences.

One of the most significant research goals of my lab during the last two decades was the development of safe, nontoxic aminoglycoside (AGs) drugs. We have designed generations of new AGs that are more effective and less toxic than commercially known antibiotics. In addition, we have further developed AG compounds that can overcome genetically inherited diseases, which are induced by the presence of stop-codon mutations. This type of mutations account for about 5-10% of each of 1,800 genetic diseases known to date. Our developed new AGs can allow the ribosome to “read through” the mutation and translate the entire protein, thus alleviating diseases, such as cystic fibroses, Usher’s syndrome, Hurler syndrome, cancer and more. Our remarkable achievement, which was supported by the BSF, NIH and other grants, has eventually led to the establishment of Eloxx Pharmaceuticals in the United States and Israel. One of the developed compounds, ELX-02, is currently in clinical phase 2 trials against stop codon mutations in cystic fibrosis and cystinosis diseases. Other AGs developed in our lab were found to be effective for the treatment of Leishmania, a persistent parasite found in many places around the world, including Israel. Amongst our inventions are bi-functional AGs, which are designed to combat resistant strains of bacteria, as well the innovative concept of catalytic antibiotics